Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Artigo em Inglês | MEDLINE | ID: mdl-38220046

RESUMO

Universal hearing screening offers unique possibilities for detection of congenital deafness as a consequence of congenital cytomegalovirus (CMVc) infection, so its selective study in the case of a failed test could be a non-negligible screening opportunity while other guidelines covering the possibility of universal screening are adopted. The aim of this study is to analyse the possibility of selective screening for CMVc after an altered hearing test in a regional hospital. During the period studied, the results obtained were unsatisfactory, especially in children born outside the hospital of residence, showing an excessive delay in hearing screening in many cases and in the few cases where CMVc screening could be performed, only 30% had the test ordered in a timely manner. The reasons for this are varied and the solution is to include selective screening for CMVc in the hearing screening programme. This implies shortening the timing of the hearing screening protocol to allow CMVc testing in saliva or urine (preferably) before 21 days of age and providing screening programmes with the necessary staff and time to perform it properly.


Assuntos
Infecções por Citomegalovirus , Testes Auditivos , Triagem Neonatal , Humanos , Infecções por Citomegalovirus/congênito , Infecções por Citomegalovirus/diagnóstico , Recém-Nascido , Triagem Neonatal/métodos , Centros de Cuidados de Saúde Secundários , Feminino , Surdez/congênito , Surdez/diagnóstico , Masculino
2.
Audiol Res ; 13(4): 655-669, 2023 Aug 15.
Artigo em Inglês | MEDLINE | ID: mdl-37622934

RESUMO

Second-level hospitals face peculiarities that make it difficult to implement hearing rescreening protocols, which is also common in other settings. This study analyzes the hearing rescreening process in these kinds of hospitals. A total of 1130 individuals were included; in this cohort, 61.07% were hospital newborns who failed their first otoacoustic emission test after birth (n = 679) or were unable to perform the test (n = 11), and who were then referred to an outpatient clinic. The remaining 38.93% were individuals born in another hospital with their first test conducted in the outpatient clinic (n = 440). A high number of rescreenings were made outside of the recommended time frame, mainly in children referred from another hospital. There was a high lost-to-follow-up rate, especially regarding otolaryngologist referrals. Neonatal hearing screening at second-level hospitals is difficult because of staffing and time constraints. This results in turnaround times that are longer than recommended, interfering with the timely detection of hearing loss. This is particularly serious in outpatient children with impaired screening. Referral to out-of-town centers leads to unacceptable follow-up loss. Legislative support for all these rescreening issues is necessary. In this article, these findings are discussed and some solutions are proposed.

3.
Acta otorrinolaringol. esp ; 69(5): 291-296, sept.-oct. 2018. tab
Artigo em Espanhol | IBECS | ID: ibc-178715

RESUMO

INTRODUCCIÓN: Las recomendaciones de la Comisión Nacional para la Detección Precoz de la Hipoacusia (CODEPEH) aconsejan re-valorar la audición de aquellos niños que hayan sufrido algún evento potencialmente dañino para la audición como es la utilización de antibióticos ototóxicos como la gentamicina. Las otoemisiones evocadas son un buen método de evaluación de la integridad de la función coclear. MATERIAL Y MÉTODO: Se presenta un estudio prospectivo que incluye a 92 niños, sin otros factores de riesgo auditivo, en los que se pautó tratamiento con gentamicina intravenosa por riesgo séptico/sepsis o infección urinaria y en los que se realizaron otoemisiones seriadas: al ingreso, al finalizar el tratamiento y al mes del alta (si estaban alteradas). RESULTADOS: Ningún sujeto presentó otoemisiones alteradas al final del seguimiento. CONCLUSIÓN: La gentamicina parece un antibiótico seguro en tratamientos con una duración < 10 días y a las dosis descritas. Las otoemisiones son un método barato, rápido, incruento y fiable para comprobar la posible ototoxicidad por gentamicina. Su realización podría ahorrar la determinación de niveles del fármaco


INTRODUCTION: The National Commission for the Early Detection of Hearing Loss (CODEPEH) recommends the re-evaluation of hearing in children who have suffered any potentially harmful event, such as the prescription of ototoxic antibiotics such as gentamicin. The evoked otoacoustic emissions (EOAE) are a good method for assessing the integrity of cochlear functionality. MATERIAL AND METHOD: A prospective study is presented, including 92 children who were treated with intravenous gentamicin for septic risk/sepsis or urinary tract infection. The children underwent serial EOAE: on admission, at the end of treatment and one month later (if altered on discharge). RESULTS: In the end, none of the subjects were affected by the treatment. CONCLUSION: Gentamicin appears to be a safe antibiotic in treatments lasting < 10 days and at the doses described. EOAE are an inexpensive, fast, non-invasive and reliable method to check for gentamicin ototoxicity. This could save in the determination of drug levels


Assuntos
Humanos , Masculino , Feminino , Recém-Nascido , Lactente , Antibacterianos/farmacologia , Gentamicinas/farmacologia , Emissões Otoacústicas Espontâneas , Estudos Prospectivos , Centros de Cuidados de Saúde Secundários
4.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-29519695

RESUMO

INTRODUCTION: The National Commission for the Early Detection of Hearing Loss (CODEPEH) recommends the re-evaluation of hearing in children who have suffered any potentially harmful event, such as the prescription of ototoxic antibiotics such as gentamicin. The evoked otoacoustic emissions (EOAE) are a good method for assessing the integrity of cochlear functionality. MATERIAL AND METHOD: A prospective study is presented, including 92 children who were treated with intravenous gentamicin for septic risk/sepsis or urinary tract infection. The children underwent serial EOAE: on admission, at the end of treatment and one month later (if altered on discharge). RESULTS: In the end, none of the subjects were affected by the treatment. CONCLUSION: Gentamicin appears to be a safe antibiotic in treatments lasting <10days and at the doses described. EOAE are an inexpensive, fast, non-invasive and reliable method to check for gentamicin ototoxicity. This could save in the determination of drug levels.


Assuntos
Antibacterianos/farmacologia , Gentamicinas/farmacologia , Emissões Otoacústicas Espontâneas/efeitos dos fármacos , Feminino , Humanos , Lactente , Recém-Nascido , Masculino , Estudos Prospectivos , Centros de Cuidados de Saúde Secundários
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...